Neue Novavax: Anstieg nach 1:20 Re-Split

Der Kurs ist meiner Meinung nach primär wegen Ocugen abgesagt. Auch wenn man beide schwer vergleichen kann. Am Ende gings gut wieder in die alte Richtung.  

nichts mit Ocugen zu tun.
Der komplette Markt (Biosektor) ist abgesackt und hat sich wieder erholt. Der Vergleich Novavax mit Ocugen ist sowieso ein schlechter Scherz. Nur meine Meinung.
 

Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine

- Recombinant spike protein antigen (rS-B.1.351) based on the Beta (B.1.351) virus lineage highly immunogenic in mice and produced neutralizing antibodies
- Primates boosted with rS-B.1.351 induced strong neutralizing immune response to original SARS-CoV-2, Alpha (B.1.1.7) and Beta (B.1.351) variant strains
- Humans immunized with NVX-CoV2373 demonstrated robust antibody responses to original SARS-CoV-2, as well as Alpha (B.1.1.7) and Beta (B.1.351) variant strains
- Data available ahead of publication via preprint server, bioRxiv

…. This work demonstrates that variant vaccines that protect against these newly emerging variants have the potential to be highly effective and may produce broader protection against variants we know of and those that will arise in the future. Clinical trials will provide further evidence on the effectiveness of variant vaccines."

https://ir.novavax.com/news-releases/...a-three-complementary-studies  

Italy halts AstraZeneca vaccine for under-60s

https://www.reuters.com/world/europe/...ter-teenager-dies-2021-06-11/

 

FDA Forces Johnson & Johnson To Throw Out 60 Million Doses Of Covid-19 Vaccine

…Johnson & Johnson must destroy 60 million doses of its Covid-19 vaccine because they may be contaminated, according to a New York Times report, while millions of its unused doses were given extra shelf life by regulators.

https://www.forbes.com/sites/graisondangor/2021/...n-for-bad-batches/  

The next generation Covid-19 vaccines seeking a slice of the market

…Indeed, newcomer Novavax is forecast to overtake Moderna as the second-largest Covid-19 vaccine maker by revenue next year, with estimated sales of $17.9bn in 2022, according to Airfinity, a London-based analytics company.

https://www.ft.com/content/846c00e4-06ba-417d-978c-98caef7f605a

Nächste Woche geht die Luzie ab!  

Novavax Will Make Announcement About It's COVID-19 Vaccine Data Next Week

https://youtu.be/Tbz8Z0E7lIU  

AstraZeneca shots should be halted for over-60s - EMA official

https://www.reuters.com/business/...-60s-too-ema-official-2021-06-13/  

warum sollte nächste  Woche    "  die Luzie abgehen "
Zulassungspläne sind doch auf 3. Quartal verschoben wurden ?  

siehe meine Postings, News vom Freitag sowie FT Artikel.
Die Zulassung wird uns noch einen weitern Schub geben.
Nächste Woche sehen wir Kurse von $22 bis $250, nur meine Meinung bzw. Einschätzung.  

Und am Montag ist noch Stans Auftritt bei der BIO Digital 2021.


 

das war mir schon klar , na da lassen wir uns doch mal überraschen  

promises on COVID-19, climate, mentions of China

…Canada will donate an additional 13 million doses out of its planned surplus supply.

The majority of it (7.3 million doses) will be the Novavax vaccine, which has not yet been approved by Health Canada. There will be 4.3 million doses from the AstraZeneca-Oxford supply and 1.3 million from the Johnson & Johnson stream.

https://www.cbc.ca/news/politics/canada-g7-commitments-1.6064143  

+10%

Novavax 90% efficacy

https://twitter.com/Novavax/status/1404379473085091843

NEW DATA RELEASE: Novavax #COVID19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial https://bit.ly/3iD7CZl
 

Wie sagt man heutzutage so schön:

To the moon :)

Spaß bei Seite. Es ist halt die Frage wie viel schon eingepreist ist und wie viel Fantasie noch drin ist. Ich hoffe, dass wir neue ATH's sehen  

Da novavax schon Verträge geschlossen hat, dürfte noch etwas mehr dahinter sein.

Timeline ist hier aber auch 3 Monate...  

Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results

https://time.com/5946225/..._oEl-hlvAo5unlkDEdDdbmd4KUt60uGfmhIgITOUM  

wird den Kurs untermauern und sich wie ein Dominoeffekt auf die Auftragslage auswirken, denn die Auftraggeber warten schon an der Seitenlinie, nur meine Meinung.  

…Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said, "It's really very impressive," noting that the vaccine was as good as the most effective shots developed so far during the pandemic. "It's very important for the world's population to have, yet again, another highly efficacious vaccine that looks in its trial to have a good safety profile," Fauci told the Washington Post.

As heartening as the results were, the vaccine may not become a key player in the pandemic until late summer or fall.

Erck told the Post that Novavax will apply for regulatory clearance from a half-dozen countries in the third quarter, which begins in July. With tens of millions of doses already in hand, the company plans to boost manufacturing to produce 100 million doses a month by the end of September and 150 million doses a month in the last three months of the year.

https://www.usnews.com/news/health-news/articles/...s-in-latest-trial  

Novavax-Vakzin wirksamer als bisher gedacht

Das Portfolio der verfügbaren Corona-Impfstoffe könnte schon bald um ein weiteres offenbar sehr erfolgreiches Vakzin wachsen. Das US-Unternehmen Novavax berichtet von sehr guten Studiendaten - selbst bei Virusvarianten, die die Firma bislang nicht identifizieren konnte.

Das US-Biotechunternehmen Novavax plant nach weiteren positiven Studienergebnissen mit seinem Covid-19-Impfstoff nun einen Zulassungsantrag im dritten Quartal. In einer Studie mit rund 30.000 Teilnehmern in den USA und Mexiko zeigte das Vakzin eine Wirksamkeit von mehr als 93 Prozent gegen die vorherrschenden Virusvarianten, wie das Unternehmen mitteilte. Am Aktienmarkt ging es vorbörslich für die Papiere deutlich nach oben.

Während der Untersuchung sei die erstmals in Großbritannien nachgewiesene Alpha-Variante B.1.1.7 am häufigsten aufgetreten. Studienteilnehmer hätten sich aber auch mit den Varianten aus Brasilien, Südafrika und Indien infiziert, sagte Novavax-Forschungschef Gregory Glenn.

Der Impfstoff schützte Studienteilnehmer, die ein hohes Risiko für einen schweren Verlauf hatten, demnach zu 91 Prozent und zeigte eine Wirksamkeit von 100 Prozent bei der Vorbeugung mittelschwerer und schwerer Covid-19-Fälle. Gegen Varianten, die Novavax nicht identifizieren konnte, sei er zu etwa 70 Prozent wirksam gewesen, sagte Glenn.

Novavax verwendet für sein Vakzin NVX-CoV2373 das sogenannte Spike-Protein von Sars-CoV-2 und reproduziert es massenhaft in Insektenzellen. Das menschliche Immunsystem bildet dann Antikörper gegen das Spike-Protein und kann dadurch eine Covid-19-Erkrankung abwehren.

Novavax hatte bereits zu Jahresbeginn erste Daten aus seiner Studie in Großbritannien vorgelegt, wonach das Vakzin eine Wirksamkeit von gut 89 Prozent zeigte. Das Unternehmen hatte aber mehrmals seine Produktionsziele verschieben müssen und kämpfte mit Engpässen bei Materialien und Zubehör zur Herstellung seines Impfstoffs. Bis Ende des dritten Quartals will der Konzern 100 Millionen Impfdosen pro Monat herstellen und 150 Millionen Dosen monatlich bis Ende des vierten Quartals.

https://www.n-tv.de/wirtschaft/...TtmuwodLi0KUw5fw#Echobox=1623682832  

A Vaccine the World Badly Needs Looks Better Than Ever

Novavax’s shot has been beset by delays and setbacks, but new data suggests it is a highly effective shot that could play a big role in the global pandemic fight.

Research and manufacturing delays have dogged the arrival of a Covid-19 vaccine from Novavax Inc., one of only six selected by the U.S. government's Operation Warp Speed for a large order. At one point in May, the company’s shares were down 62% from a February high. On Monday, though, Novavax took a step toward a comeback, announcing that its vaccine was 90.4% effective in preventing mild and moderate Covid in a large trial in the U.S. and Mexico and prevented all severe disease.

Late or not, the promising data suggests that Novavax's effort could be crucial in a pandemic fight that won't end soon. Even for those jaded by dozens of data releases, this is an impressive result that should help pave the way for rapid approval and rollout in the third quarter. The vaccine won’t see much initial use in the U.S., where the vaccination rate is already high, but it will be instrumental in inoculating the world, which is vital in the effort to tame the virus, keep variants at bay and minimize the human and economic damage.

While comparing clinical-trial data is fraught, especially during an evolving pandemic, the Novavax results appear to be among the best so far. Everyone pays attention to the headline number, and Novavax fell short of the 94% and 95% efficacy reported respectively by mRNA vaccines from Moderna Inc. and Pfizer Inc.'s collaboration with BioNTech SE, but context matters.

Here’s what makes the shot a standout: Novavax's trial took place when variants began to dominate; they were only a theoretical concern during mRNA vaccine tests. In the U.S. trial, the vaccine was 93% effective against variants of concern and interest. The data isn't perfect; Novavax's results are a bit less conclusive than those from the mRNA vaccines because it recorded fewer infections as cases declined. And most variant infections came from the so-called alpha variant first identified in Britain, limiting information about others such as the concerning delta variant, which was first discovered in India. But the study is still highly promising, especially on top of similar results from an earlier trial in the U.K. The vaccine did allow more infections in a trial in South Africa dominated by the beta strain first identified there, which partially evades vaccines. But notably, the shot still prevented all severe disease and death. The vaccine may be delayed, but the timing means more confidence that it works in the current environment.

The shot's combination of efficacy and availability is particularly exciting. Novavax has pledged 1.1 billion vaccines to COVAX, the organization leading the effort to vaccinate lower-income countries. Insufficient funding and manufacturing delays have left the group struggling to hit targets; Novavax’s doses are badly needed. The company hopes to make 100 million doses a month by the end of the third quarter and 150 million in the fourth quarter. The vaccine is also more stable and easily stored than mRNA vaccines, which will be helpful in broad distribution.

Novavax has also been especially willing to license its vaccine to manufacturers in other parts of the world, including South Korea's SK Biosciences Co., Japan’s Takeda Pharmaceutical Co. and the Serum Institute of India. Once those plants are up to speed, they should help more quickly vaccinate their home countries and further increase global availability.

On top of setting the vaccine up as a key tool this year, Monday's data suggests Novavax will have a long-term role in keeping the virus tamped down, which had been an unknown for investors. It's a validation of the underlying technology, which uses tiny virus protein fragments and an immune-boosting substance called an adjuvant to prompt a protective response. The company is testing a third dose as a six-month booster, and early data suggests it produces a strong immune response. Novavax is also part of a study in the U.K. examining mixing different vaccines, and good results could bode well for broad booster use. The company is also developing vaccines tailored to specific strains, and a combination flu and Covid shot, which could see use for years to come.

Novavax still has to deliver on its data by winning approval, delivering doses and speeding the next generation of shots to market. But at the very least, we know that when its vaccines arrive, they'll do a great deal of good.


https://www.bloomberg.com/opinion/articles/...resses-in-variant-fight  

Novavax Vaccine Is Real Competition for Pfizer and Moderna

https://www.barrons.com/articles/...YvFHjkVw0gC_AdwHv7rpXZNODigsrV2xs  

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
Jun 14, 2021 at 4:05 PM EDT

- COVID-19 vaccine candidate efficacy in those 18 to <65 years old was preserved in influenza vaccine recipients
- Influenza vaccine immunogenicity preserved
- Study demonstrated no early safety concerns
- Data available ahead of publication via preprint server, medRxiv

https://ir.novavax.com/news-releases/...first-study-influenza-vaccine  

Gute Nachrichten und die Novavax-Aktie schmiert von +15% auf Minus ab. Warum?  

war echt verrückt und typisch für Novavax.
Heute gab es ein neues Kursziel von Cantor Fitzgerald von $217 auf $272.